Roche Holding Ltd

ROG

Equity

ISIN CH0012032048 / Valor 1203204

SIX Swiss Exchange (2026-06-25)

CHF 335.30+0.99%

Roche Holding Ltd
UMushroom community rating:

4.39 44 votes No rating yet

NegativeNeutralPositive

About company

Roche Holding Ltd is a Swiss multinational healthcare company headquartered in Basel that operates primarily through two businesses: Pharmaceuticals and Diagnostics. The Pharmaceuticals division develops and commercializes prescription medicines—particularly biologics and targeted therapies—across oncology, immunology, infectious diseases, neuroscience and ophthalmology, and includes the majority-owned US biotech unit Genentech; several well-known oncology drugs in its portfolio have driven its commercial profile. The Diagnostics division supplies laboratory and point-of-care instruments, reagents and software for clinical chemistry, molecular diagnostics, tissue-based cancer testing and diabetes care (including blood‑glucose systems), serving hospitals, clinical labs and blood‑screening organizations worldwide. Roche is research-intensive, invests heavily in R&D and in partnerships or acquisitions with other biotech firms to advance targeted and personalized medicine, and is publicly listed with a broad global commercialization and distribution footprint.

Summarized from source with an LLMView SourceSector: Healthcare

Sales

Group sales growth +7% at CER for FY 2025, with Pharma sales up +9% and Diagnostics up +2% (the Diagnostics result was achieved despite China healthcare pricing reforms).

Profitability

Strong operating performance: Core operating profit (Core OP) increased +13% and Core OP margin expanded by +1.9 percentage points year‑over‑year (all at CER).

Earnings per share

Core diluted EPS rose +11% for the year (at CER), ahead of prior guidance ranges described by management.

Loss of exclusivity (LOE) impact

Full‑year LOE impact was reported at CHF ‑0.7 billion (losses of exclusivity on several legacy products were reflected in results).

Dividend

The Board proposed a further increase in the dividend to CHF 9.80 per share for 2025.

Guidance outcome

Roche stated it achieved its upgraded 2025 guidance — sales outperformance versus prior mid‑single‑digit guidance and stronger than expected Core EPS growth (delivering the higher end outcome announced).

Q4 2025 / Pipeline and regulatory milestones

Q4 2025 and YTD milestones highlighted: EU approval of Gazyva in lupus nephritis, US/EU approval of Lunsumio SC in 3L+ follicular lymphoma, a US filing for giredestrant in post‑CDKi ER+/HER2‑ mBC, and numerous positive Phase III readouts across multiple programs — items that management flagged as drivers for 2026+ growth.

Summarized from source with an LLMView Source

Key figures

29.3%1Y

21.3%3Y

-2.76%5Y

Performance

23.0%1Y

21.3%3Y

20.4%5Y

Volatility